Achilles Therapeutics has agreed to test Ori’s manufacturing platform in its proprietary clonal neoantigen T-cell (cNeT) therapy manufacturing process
Ori Biotech, an innovator in cell and gene therapy (CGT) manufacturing, has announced a partnership with Achilles Therapeutics to test the application of Ori's novel manufacturing technology to Achilles' manufacturing process.
High-quality, low-cost, high throughput cell and gene therapy manufacturing continues to be a significant challenge for the industry. The resulting variability and high cost of goods are contributing to the current lack of wide-spread patient access to this new generation of life-saving treatments.
Therapeutics developers, regulators and technology providers are all seeking to identify innovative approaches for efficient product manufacturing.
"The team at Ori are excited to partner with innovative companies like Achilles who want to address manufacturing early in their lifecycle so that they can quickly bring their products to patients at scale," said Jason Foster, CEO of Ori Biotech. "We believe that collaborating with therapy developers early is key to maximising the scalability and repeatability of these often-complicated manufacturing processes."
"Achilles is excited to start testing the Ori manufacturing platform in our proprietary clonal neoantigen T-cell (cNeT) therapy manufacturing process," said Ed Samuel, SVP Manufacturing at Achilles Therapeutics. "Achilles is at a transformational stage in its development with the recent initiation of our first-in-human clinical studies."
Samuel added: "By harnessing the immune system to destroy cancer cells our cNeT therapy platform could fundamentally change how cancer is treated. Looking to emerging technologies to support our long-term strategy for a fully automated manufacturing process is central to Achilles" plans for scaling up our production capabilities to deliver personalised cell therapies."
Farlan Veraitch, Co-Founder and CSO of Ori Biotech added: "It is always great to work with the forward-thinking leaders in cell and gene therapy, like Achilles, who are focused on innovating across the board, not just clinically and scientifically but also technologically. We see huge potential for the future of this partnership."